These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 17353240

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Design of tenofovir-UC781 combination microbicide vaginal gels.
    Kiser PF, Mahalingam A, Fabian J, Smith E, Damian FR, Peters JJ, Katz DF, Elgendy H, Clark MR, Friend DR.
    J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
    [Abstract] [Full Text] [Related]

  • 4. Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.
    Richardson-Harman N, Mauck C, McGowan I, Anton P.
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1422-33. PubMed ID: 22900504
    [Abstract] [Full Text] [Related]

  • 5. Macaca fascicularis vs. Macaca nemestrina as a model for topical microbicide safety studies.
    Patton DL, Sweeney YC, Tsai CC, Hillier SL.
    J Med Primatol; 2004 Apr; 33(2):105-8. PubMed ID: 15061723
    [Abstract] [Full Text] [Related]

  • 6. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.
    Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, Cortina G, Tanner K, Boscardin J, Cumberland WG, Zhou Y, Ventuneac A, Carballo-Diéguez A, Rabe L, McCormick T, Gabelnick H, Mauck C, McGowan I.
    PLoS One; 2011 Apr; 6(9):e23243. PubMed ID: 21969851
    [Abstract] [Full Text] [Related]

  • 7. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.
    Hossain MM, Parniak MA.
    J Virol; 2006 May; 80(9):4440-6. PubMed ID: 16611904
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model.
    Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL.
    Antimicrob Agents Chemother; 2006 May; 50(5):1696-700. PubMed ID: 16641437
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781.
    Yang H, Parniak MA, Isaacs CE, Hillier SL, Rohan LC.
    AAPS J; 2008 Dec; 10(4):606-13. PubMed ID: 19089644
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development and characterisation of a self-microemulsifying drug delivery systems (SMEDDSs) for the vaginal administration of the antiretroviral UC-781.
    McConville C, Friend D.
    Eur J Pharm Biopharm; 2013 Apr; 83(3):322-9. PubMed ID: 23159711
    [Abstract] [Full Text] [Related]

  • 15. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.
    Cost M, Dezzutti CS, Clark MR, Friend DR, Akil A, Rohan LC.
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3058-66. PubMed ID: 22430977
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men.
    Ventuneac A, Carballo-Diéguez A, McGowan I, Dennis R, Adler A, Khanukhova E, Price C, Saunders T, Siboliban C, Anton P.
    AIDS Behav; 2010 Jun; 14(3):618-28. PubMed ID: 19757017
    [Abstract] [Full Text] [Related]

  • 19. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.
    Schwartz JL, Kovalevsky G, Lai JJ, Ballagh SA, McCormick T, Douville K, Mauck CK, Callahan MM.
    Sex Transm Dis; 2008 Apr; 35(4):414-9. PubMed ID: 18362865
    [Abstract] [Full Text] [Related]

  • 20. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor.
    Borkow G, Salomon H, Wainberg MA, Parniak MA.
    AIDS Res Hum Retroviruses; 2002 Jul 01; 18(10):711-4. PubMed ID: 12167278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.